
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Details : 18-F JK-PSMA-7 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
November 18, 2022
